MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
ENDRA Life Sciences Net Income 2011-2026 | NDRA
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.03 M | -11.5 M | -10.1 M | -13.2 M | -11.2 M | -11.7 M | -13.3 M | -9.8 M | -5.38 M | -2.78 M | -2.28 M | -2.18 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.18 M | -13.3 M | -8.37 M |
Quarterly Net Income ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.6 M | -1.23 M | -1.04 M | - | -2.35 M | -2.23 M | -2.78 M | - | -3.1 M | -2.56 M | -2.94 M | - | -3.44 M | -3.59 M | -2.86 M | - | -2.66 M | -3.2 M | -2.27 M | - | -3.26 M | -2.89 M | -3.32 M | - | -3.41 M | -2.33 M | -2.75 M | - | -2.76 M | -1.85 M | -2.83 M | - | -909 K | -1.43 M | -742 K | - | -978 K | -729 K | -379 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -379 K | -3.59 M | -2.28 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 15.85 | -2.49 % | $ 171 M |  China |
 |
Agilent Technologies
A
|
1.21 B | $ 115.06 | -0.29 % | $ 35 B |  USA |
 |
Aspira Women's Health
AWH
|
-12.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-26.4 M | $ 1.13 | -2.59 % | $ 6.15 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.1 M | - | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-21.4 M | $ 16.05 | -3.83 % | $ 855 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
-46.9 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-208 M | - | - | $ 19.8 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
18.2 M | $ 23.13 | -1.28 % | $ 642 M | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
Interpace Biosciences
IDXG
|
24.6 M | $ 2.3 | - | $ 10.2 M | USA |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 175.65 | 0.06 % | $ 8.71 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
Danaher Corporation
DHR
|
3.61 B | $ 189.61 | -1.7 % | $ 135 B | USA |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Medpace Holdings
MEDP
|
451 M | $ 493.53 | -1.59 % | $ 14.2 B | USA |
 |
Illumina
ILMN
|
-1.22 B | $ 120.93 | -2.22 % | $ 19.2 B | USA |
 |
Fulgent Genetics
FLGT
|
-42.7 M | $ 14.43 | -3.93 % | $ 436 M | USA |
 |
Myriad Genetics
MYGN
|
-366 M | $ 4.35 | -2.03 % | $ 403 M | USA |
 |
NeoGenomics
NEO
|
-108 M | $ 7.69 | -3.17 % | $ 985 M | USA |
 |
Guardant Health
GH
|
-416 M | $ 78.6 | -9.83 % | $ 9.85 B | USA |
 |
QIAGEN N.V.
QGEN
|
425 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
-10.9 M | $ 2.69 | -1.82 % | $ 87.3 K | USA |
 |
Biomerica
BMRA
|
-4.97 M | $ 2.13 | -0.9 % | $ 4.89 M | USA |
 |
Invitae Corporation
NVTA
|
-99.8 M | - | - | $ 21.2 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
3.32 B | $ 28.31 | 0.62 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
791 M | $ 106.81 | 0.1 % | $ 8.81 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
876 M | $ 260.93 | -4.51 % | $ 21.7 B | USA |
 |
Natera
NTRA
|
-548 M | $ 193.03 | -4.91 % | $ 19 B | USA |
 |
Celcuity
CELC
|
-177 M | $ 117.14 | -6.02 % | $ 5.48 B | USA |
 |
Lantheus Holdings
LNTH
|
234 M | $ 80.59 | -1.03 % | $ 5.44 B | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Quest Diagnostics Incorporated
DGX
|
992 M | $ 191.51 | -3.19 % | $ 21.3 B | USA |
 |
Neogen Corporation
NEOG
|
-1.09 B | $ 9.42 | -6.13 % | $ 2.04 B | USA |
 |
Organovo Holdings
ONVO
|
-2.49 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
12 M | - | -16.95 % | $ 1.54 M | USA |
 |
National Research Corporation
NRC
|
11.6 M | $ 16.48 | -3.34 % | $ 369 M | USA |